Literature DB >> 15504625

Opioids in renal failure and dialysis patients.

Mervyn Dean1.   

Abstract

This article reviews the literature pertaining to the metabolism of several of the commonly used opioids, and the known activity of their metabolites. The effect of renal failure on the pharmacokinetics of these drugs and metabolites is then reviewed. Finally, the effect of renal dialysis on opioid drugs and metabolites is reviewed. Based on the review, it is recommended that morphine and codeine are avoided in renal failure/dialysis patients; hydromorphone or oxycodone are used with caution and close monitoring; and that methadone and fentanyl/sufentanil appear to be safe to use. Note is made that the "safe" drugs in renal failure are also the least dialyzable.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15504625     DOI: 10.1016/j.jpainsymman.2004.02.021

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  70 in total

Review 1.  Implications of opioid analgesia for medically complicated patients.

Authors:  Howard Smith; Patricia Bruckenthal
Journal:  Drugs Aging       Date:  2010-05       Impact factor: 3.923

2.  [Cancer pain in palliative medicine].

Authors:  R Laufenberg-Feldmann; R Schwab; R Rolke; M Weber
Journal:  Internist (Berl)       Date:  2012-02       Impact factor: 0.743

3.  Swallowing difficulties: a prognostic signpost.

Authors:  Romayne Gallagher
Journal:  Can Fam Physician       Date:  2011-12       Impact factor: 3.275

Review 4.  [Cancer pain in palliative medicine].

Authors:  R Laufenberg-Feldmann; R Schwab; R Rolke; M Weber
Journal:  Anaesthesist       Date:  2012-05       Impact factor: 1.041

Review 5.  Medical safety in the care of the person with end-stage kidney disease.

Authors:  John V Duronville; Clarissa J Diamantidis
Journal:  Semin Dial       Date:  2018-01-07       Impact factor: 3.455

6.  Opioid-induced neurotoxicity.

Authors:  Romayne Gallagher
Journal:  Can Fam Physician       Date:  2007-03       Impact factor: 3.275

Review 7.  [Update palliative pain therapy].

Authors:  R Rolke; S Rolke; S Hiddemann; M Mücke; H Cuhls; L Radbruch; F Elsner; V Peuckmann-Post
Journal:  Internist (Berl)       Date:  2016-10       Impact factor: 0.743

Review 8.  Opioid metabolism.

Authors:  Howard S Smith
Journal:  Mayo Clin Proc       Date:  2009-07       Impact factor: 7.616

9.  Long-term efficacy of OROS® hydromorphone combined with pregabalin for chronic non-cancer neuropathic pain.

Authors:  Mario Dauri; Marzia Lazzari; Manuela Casali; Giuseppe Tufaro; Elisabetta Sabato; Alessandro Fabrizio Sabato
Journal:  Clin Drug Investig       Date:  2014-05       Impact factor: 2.859

10.  An open-label, 1-year extension study of the long-term safety and efficacy of once-daily OROS(R) hydromorphone in patients with chronic cancer pain.

Authors:  Magdi Hanna; Alberto Tuca; John Thipphawong
Journal:  BMC Palliat Care       Date:  2009-09-15       Impact factor: 3.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.